TechWald Holding S.p.A.

What TechWald Holding S.p.A. does

TechWald Holding S.p.A. is an Italian operational holding company founded in 2018 that invests in early-to-development-stage medical technology (MedTech) companies across cardiovascular, neurovascular, neuromodulation, metabolic disease, and surgical visualization domains. The firm holds equity stakes in approximately 10 portfolio companies and provides not only capital but also hands-on operational support, including board participation, general management, clinical and medical guidance, market access, health technology assessment (HTA), regulatory strategy, and commercial and organizational setup. Its portfolio includes Valcare Medical (majority-owned following an April 2024 acquisition), SoniVie (TIVUS ultrasound denervation; subject to a Boston Scientific acquisition agreement in March 2025), Nitinotes (EndoZip automated endoscopic suturing), SentiAR (CommandEP mixed reality cardiac ablation guidance, FDA 510(k) cleared), Lymphatica Medtech (LymphoDrain), Bendit Technologies (steerable microcatheters, FDA 510(k) cleared), Beyeonics Surgical, ElectroPhysiology Frontiers, EP Solutions, and Inotec AMD. The founding team is composed of medical device executives with 10-25+ years of experience at healthcare multinationals across sales, marketing, business development, clinical development, and regulatory affairs at European and global level.

TechWald's core technology exposure spans proprietary portfolio devices such as transcatheter mitral valve annuloplasty rings (AMEND), intravascular ultrasound denervation catheters (TIVUS), steerable microcatheters free from guidewires/pulling wires (Bendit), automated endoscopic suturing systems (EndoZip), implantable lymphatic drainage devices (LymphoDrain), and mixed-reality cardiac visualization (CommandEP). Headquartered in Turin, Italy with offices in Milan and a regional presence in Israel (Tel Aviv/Caesarea), the firm serves portfolio companies and ultimately hospitals, cardiac centers, and interventional healthcare providers as end-customers of the underlying medical devices.

TechWald's business model is that of an operational holding company: revenue is derived primarily from equity appreciation and exit events from portfolio companies rather than direct product sales or licensing royalties. Confirmed monetization milestones include the Boston Scientific agreement to acquire SoniVie for approximately $360M upfront (for the 90% stake not already owned) plus up to $180M upon a regulatory milestone, representing a ~$540M total deal value on a 100% basis. TechWald has also participated in Series A through C rounds aggregating over $85M across portfolio companies (SoniVie $60M Series C; SentiAR $8.5M Series B; Lymphatica €17.9M Series B; Nitinotes $7.1M Series A1). Revenue at the holding-company level is not publicly disclosed.

Name

TechWald Holding S.p.A.

Legal name

TechWald Holding S.p.A.

Website

https://techwald.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

TechWald Holding S.p.A. is an Italian operational holding company founded in 2018 that takes equity stakes in early-stage MedTech companies across cardiovascular, neurovascular, metabolic, and surgical visualization domains, providing capital plus operational, clinical, regulatory, and commercial support to a portfolio of approximately ten companies.

Ownership category

akta.pro rank

Product category

MedTech Holding & Investment Services

NAICS

Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industries

Industry-Specialist Buyout (Sector-Focused) (FSANABAE), Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Operational holding company
• Medical device investment
• Medtech venture capital
• Cardiovascular devices
• Minimally invasive surgery

Headquarters

HQ city

Torino

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Operational Holding Company Services: TechWald provides managerial activities, strategic orientation, development support, coordination, and management of shareholdings acquired as stable equity investments in the Healthcare/MedTech sector. Revenue is derived from equity appreciation and exit events from portfolio companies.
2. Portfolio Company Equity Stakes: TechWald holds equity stakes in multiple MedTech portfolio companies. Returns are realized through portfolio company exits including acquisitions and IPOs, such as Boston Scientific's acquisition of SoniVie and potential exits from Valcare Medical, Nitinotes, and other portfolio companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

TechWald Holding S.p.A. is an operational holding company that invests equity capital and provides operational management support to early-stage MedTech companies. The company takes equity stakes (minority or majority) in portfolio firms developing proprietary medical devices across cardiovascular, neurovascular, neuromodulation, metabolic disease, and surgical visualization domains, then supplies board participation, clinical/medical guidance, market access, regulatory strategy, and commercial setup. Returns are generated through equity appreciation and exit events such as strategic acquisitions.

Differentiator

Problem solved

Functional benefit

Products and services

• Operational Holding & Investment Services Operational and financial holding services for early-stage MedTech companies, including board participation, general management, clinical/medical guidance, market access, HTA and regulatory support, and commercial/organizational setup. Provided to portfolio companies in exchange for equity stakes.
• AMEND™ Transcatheter Mitral Valve Repair System

Quantifiable outcome

• Boston Scientific agreed to acquire SoniVie for ~$360M upfront + up to $180M regulatory milestone (total ~$540M on 100% basis)
• +5 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered minor.

• BVI (Beaver-Viseltec International)minorGTM or Marketing Partner · 4 October 2021BVI announced investment and collaboration with Beyeonics Vision to commercialize Beyeonics One in the United States, with potential for rapid expansion in other territories. BVI is a purpose-built diversified global ophthalmic device company with nine decades of history and operations in more than 115 countries. The collaboration includes streamlined process to commercialize Beyeonics One in the US market.
• Nocturnal Product Development, LLCminorStrategic or Co-development Partner · 30 November 2018TechWald Holding entered a strategic global partnership with Nocturnal Product Development, LLC (Research Triangle Park, NC) to evaluate, fund, and develop innovative medical technologies. The partnership enhances TechWald's service capabilities in the US, expands its footprint into Europe and Israel, and provides access to an international funding option and physician networks. Nocturnal specializes in multi-disciplinary technology product development including electrical design, mechanical design, embedded software, optics, IOT, wireless, cloud-based applications, project management, and clinical & regulatory strategy.

Scale indicators4 records

Expansion highlights5 records

Direct peers

• Sofinnova Partners: European life sciences venture capital firm investing across MedTech, biopharma, and digital health from early to late stages. Comparable as a long-tenured, sector-specialist investor backing European and Israeli healthcare innovation.
• Forbion: Dutch life sciences VC firm investing in MedTech and biopharma across Europe and the U.S. Comparable given its multi-stage, sector-specialist approach and consistent record of exits via strategic acquisition.
• Panakès Partners: Italian venture capital firm focused on MedTech and digital health. Direct peer given co-investment in Lymphatica Medtech's €17.9M Series B and overlapping Italy-based MedTech investment thesis.
• Omega Funds: U.S./European life sciences investment firm focused on MedTech and biotech. Direct peer through participation in SoniVie's $60M Series C alongside TechWald.
• Gilde Healthcare: European healthcare investor active across MedTech, digital health, and therapeutics. Comparable sector-focused growth and buyout strategy with operational support to portfolio companies.
• EQT Life Sciences (formerly LSP): European life sciences growth and venture investor within EQT, focused on MedTech and biopharma. Comparable given its late-stage growth orientation and history of large strategic exits.
• Supernova Invest: French deep-tech and life sciences investor. Direct peer given co-investment in SoniVie's Series C and overlap in European MedTech venture-stage investing.
• Andera Partners: French private equity firm with a dedicated Life Sciences practice investing in MedTech and biotech. Direct peer through co-investment leading SoniVie's $60M Series C.

Regional players

• Indaco Venture Partners: Italian venture capital firm with healthcare and MedTech focus. Comparable given shared Italian base and orientation toward early-stage life sciences companies.

Emerging players

• cultivate(MD) Ventures: MedTech-focused seed and early-stage investor that led SentiAR's $8.5M Series B alongside TechWald. Comparable given its specialization in early-stage MedTech with operational support.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/techwald-holding-s-p-a

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TechWald Holding S.p.A.